Endogenous Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
_page-0001.jpg)
Endogenous Cushing’s syndrome (CS) is
a rare, serious endocrine disorder caused by chronic exposure to the overproduction
of cortisol. Because of the ubiquitous downstream effects of cortisol, chronic
hypercortisolism leads to multisystem morbidities, including changes in
physical appearance, cardiovascular complications (hypertension, venous
thromboembolism, peripheral edema), metabolic disturbances (insulin resistance
with impaired glucose tolerance), skeletal damage (osteopenia, osteoporosis,
skeletal fractures), impairment of reproductive and sexual function
(hypogonadism, menstrual irregularities, decreased libido, infertility), and
neuropsychiatric disorders. Endogenous CS results from chronic exposure to
excess cortisol because of adrenocorticotrophic hormone (ACTH)– dependent or
ACTH-independent etiologies. ACTH-dependent CS accounts for 80–85% of overt CS
cases; approximately 80–90% of these are attributed to Cushing’s disease (CD;
ACTH-producing pituitary adenoma), and the rest result from extrapituitary
neuroendocrine tumors causing ectopic ACTH production. ACTH-independent CS
(15–20% of CS cases) results from autonomous adrenal overproduction of cortisol
because of an adrenal adenoma, carcinoma, or bilateral hyperplasia.
·
The incidence of Endogenous Cushing’s syndrome
(CS) varies between 2.4 to 3.2 cases per one million population.
Thelansis’s “Endogenous Cushing’s
Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Endogenous Cushing’s Syndrome (CS)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Endogenous Cushing’s Syndrome (CS) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Endogenous Cushing’s Syndrome (CS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech business
environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment